Literature DB >> 22929655

Estimating the delivery efficiency of drug-loaded microbubbles in cancer cells with ultrasound and bioluminescence imaging.

Ai-Ho Liao1, Ying-Kai Li, Wei-Jiunn Lee, Ming-Fang Wu, Hao-Li Liu, Min-Liang Kuo.   

Abstract

The application of drug-loaded microbubbles (MBs) in combination with ultrasound (US), which results in an increase in capillary permeability at the site of US-sonication-induced MB destruction, may be an efficient method of localized drug delivery. This study investigated the mechanism underlying the US-mediated release of luciferin-loaded MBs through the blood vessels to targeted cells using an in vivo bioluminescence imaging (BLI) system. The luciferin-loaded MBs comprised an albumin shell with a diameter of 1234 ± 394 nm (mean ± SD) and contained 2.48 × 10⁹ bubbles/mL; within each MB, the concentration of encapsulated luciferin was 1.48 × 10⁻¹⁰ mg/bubble. The loading efficiency of luciferin in MBs was only about 19.8%, while maintaining both the bioluminescence and acoustic properties. In vitro and in vivo BLI experiments were performed to evaluate the US-mediated release of luciferin-loaded MBs. For in vitro results, the increase in light emission of luciferin-loaded albumin-shelled MBs after destruction via US sonication (6.24 ± 0.72 × 10⁷ photons/s) was significantly higher than that in the luciferin-loaded albumin-shelled MBs (3.11 ± 0.33 × 10⁷ photons/s) (p < 0.05). The efficiency of the US-mediated release of luciferin-loaded MBs in 4T1-luc2 tumor-bearing mice was also estimated. The signal intensity of the tumor with US destruction at 3 W/cm² for 30 s was significantly higher than without US destruction at 3 (p = 0.025), 5 (p = 0.013), 7 (p = 0.012) and 10 (p = 0.032) min after injecting luciferin-loaded albumin-shelled MBs. The delivery efficiency was, thus, improved with US-mediated release, allowing reduction of the total injection dose of luciferin.
Copyright © 2012 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929655     DOI: 10.1016/j.ultrasmedbio.2012.07.013

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  6 in total

Review 1.  A review of low-intensity ultrasound for cancer therapy.

Authors:  Andrew K W Wood; Chandra M Sehgal
Journal:  Ultrasound Med Biol       Date:  2015-04       Impact factor: 2.998

2.  In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.

Authors:  Xing Hua; Lina Zhou; Ping Liu; Yun He; Kaibin Tan; Qinghai Chen; Yuejuan Gao; Yunhua Gao
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles induces proliferation inhibition and apoptosis in ovarian cancer cells.

Authors:  Hongxia Liu; Shufang Chang; Jiangchuan Sun; Shenyin Zhu; Caixiu Pu; Yi Zhu; Zhigang Wang; Ronald X Xu
Journal:  Mol Pharm       Date:  2013-11-22       Impact factor: 4.939

4.  Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro.

Authors:  Yuhang Tian; Zhao Liu; Lei Zhang; Jia Zhang; Xue Han; Qiucheng Wang; Wen Cheng
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

5.  Targeted Antagonism of Vascular Endothelial Growth Factor Reduces Mortality of Mice with Acute Respiratory Distress Syndrome.

Authors:  Zhao Zhang; Dong-Shi Lu; Dan-Qing Zhang; Xin Wang; Yu Ming; Zhou-Yang Wu
Journal:  Curr Med Sci       Date:  2020-08-29

6.  Insonation of Systemically Delivered Cisplatin-Loaded Microbubbles Significantly Attenuates Nephrotoxicity of Chemotherapy in Experimental Models of Head and Neck Cancer.

Authors:  Hang-Kang Chen; Shu-Mei Zhang; Junn-Liang Chang; Hsin-Chien Chen; Yi-Chun Lin; Cheng-Ping Shih; Huey-Kang Sytwu; Mei-Cho Fang; Yuan-Yung Lin; Chao-Yin Kuo; Ai-Ho Liao; Yueng-Hsiang Chu; Chih-Hung Wang
Journal:  Cancers (Basel)       Date:  2018-09-05       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.